"Allopurinol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.
| Descriptor ID |
D000493
|
| MeSH Number(s) |
D03.633.100.759.160
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Allopurinol".
Below are MeSH descriptors whose meaning is more specific than "Allopurinol".
This graph shows the total number of publications written about "Allopurinol" by people in this website by year, and whether "Allopurinol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Allopurinol" by people in Profiles.
-
Cardiovascular morbidity and mortality in gout: is gout an independent risk factor? Expert Opin Pharmacother. 2025 Dec; 26(17):1757-1762.
-
Significant erythroid megaloblastic changes in patients treated with allopurinol during maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 11; 70(11):e30631.
-
Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease : A Population-Based Cohort Study. Ann Intern Med. 2022 04; 175(4):461-470.
-
Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice. Clin Rheumatol. 2021 Feb; 40(2):693-700.
-
Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills et al. Ann Rheum Dis. 2022 07; 81(7):e125.
-
Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma et al. Ann Rheum Dis. 2022 06; 81(6):e108.
-
Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu et al. Ann Rheum Dis. 2022 07; 81(7):e123.
-
2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020 06; 72(6):879-895.
-
Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data. Ann Rheum Dis. 2020 04; 79(4):529-535.
-
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leuk Res. 2020 02; 89:106298.